Developmental therapeutics post CDK4/6 inhibitors

被引：0
|
作者：
Yap, Yoon-Sim [1 ]
机构：
[1] Natl Canc Ctr Singapore, Dept Med Oncol, Singapore, Singapore
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.05.509
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SY30-4
引用
收藏
页码：S454 / S454
页数：1
相关论文
共 50 条
  • [1] CDK4/6 Inhibitors Represent Potential Psoriasis Therapeutics
    Brownell, I.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (11) : 2098 - 2098
  • [2] CDK4/6 inhibitors
    不详
    CHEMICAL & ENGINEERING NEWS, 2016, : 30 - 31
  • [3] CDK4 as a Prognostic Marker of Hepatocellular Carcinoma and CDK4 Inhibitors as Potential Therapeutics
    Lai, Fobao
    Fang, Yingbing
    Cheng, Cong
    Zhong, Xuejing
    Zheng, Wanrong
    Lan, Shiqian
    Peng, Quanshui
    Cai, Xiumei
    Cao, Tiantian
    Zhong, Chengqian
    Gao, Yuzhen
    CURRENT MEDICINAL CHEMISTRY, 2025, 32 (02) : 343 - 358
  • [4] CDK4/6 inhibitors prolong OS
    Killock, David
    NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (12) : 722 - 722
  • [5] CDK4/6 inhibitors: The Devil is in the Detail
    Magge, Tara
    Rajendran, Sneha
    Brufsky, Adam M.
    Foldi, Julia
    CURRENT ONCOLOGY REPORTS, 2024, 26 (06) : 665 - 678
  • [6] Development and strategies of CDK4/6 inhibitors
    Chen, Pingping
    Xu, Yinqiu
    Li, Xuanyi
    Yao, Hequan
    Lin, Kejiang
    FUTURE MEDICINAL CHEMISTRY, 2020, 12 (02) : 127 - 145
  • [7] Immunomodulatory effects of CDK4/6 inhibitors
    Zhang, Shumeng
    Xu, Qiaomai
    Sun, Wenjia
    Zhou, Jianya
    Zhou, Jianying
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2023, 1878 (04):
  • [8] CDK4/6 inhibitors prolong OS
    David Killock
    Nature Reviews Clinical Oncology, 2019, 16 : 722 - 722
  • [9] CDK4/6 inhibitors in breast cancer
    Dukelow, Tim
    Kishan, Divya
    Khasraw, Mustafa
    Murphy, Conleth G.
    ANTI-CANCER DRUGS, 2015, 26 (08) : 797 - 806
  • [10] Do CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers?
    Kalu, Nene N.
    Johnson, Faye M.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (02) : 207 - 217
12345